Neuropeptides involved in the pathophysiology of schizophrenia and major depression.
about
Hypothesizing dopaminergic genetic antecedents in schizophrenia and substance seeking behavior.Combining gene expression, demographic and clinical data in modeling disease: a case study of bipolar disorder and schizophrenia.Neuroactive peptides as putative mediators of antiepileptic ketogenic diets.Somatostatin receptor 1 and 5 double knockout mice mimic neurochemical changes of Huntington's disease transgenic miceNeuropeptides, growth factors, and cytokines: a cohort of informational molecules whose expression is up-regulated by the stress-associated slow transmitter PACAP in chromaffin cellsPain perception in schizophrenia: influence of neuropeptides, cognitive disorders, and negative symptoms.Disrupted circadian rhythms in a mouse model of schizophrenia.Comparison of beta-endorphin and CGRP levels before and after treatment for severe schizophrenia.Common mechanisms in neurodegeneration and neuroinflammation: a BrainNet Europe gene expression microarray study.Cholecystokinin activates CCKB receptors to excite cells and depress EPSCs in the rat rostral nucleus accumbens in vitro.Insulin-regulated aminopeptidase immunoreactivity is abundantly present in human hypothalamus and posterior pituitary gland, with reduced expression in paraventricular and suprachiasmatic neurons in chronic schizophrenia.Comparison of Bran-Processed and Crude Atractylodes Lancea Effects on Spleen Deficiency Syndrome in Rats.
P2860
Q30413183-193102D3-9D6C-4864-9C08-B640C6B2D689Q33383369-14D38302-3458-45DC-ABC6-B604BA3F15F6Q33569276-0B890F74-B9BD-4449-B5C0-FEF708FE5D3BQ34017941-4C4407F8-17CD-4E12-A044-67CE7284D8E4Q34280473-5530969F-C26C-4BD6-8D60-16DBC6E745A0Q35939430-4E51C92F-2877-4030-A488-2999849AB900Q35973907-F9168EDE-8F98-4F5D-8B03-6A4C413A0269Q40510768-9B4B1CB3-5991-496F-8F9E-71AB94A15BA5Q42677054-0604CFD9-EFA9-4172-B20D-B9A51DB36A4FQ44691672-C6D8C177-F31E-4BF2-A66C-700AB01B5BF8Q48377556-3581D298-E4CF-46B7-A93B-E0FEB06D3832Q55027507-5AFCF32D-29B4-470B-A2F4-35BF69F6C49F
P2860
Neuropeptides involved in the pathophysiology of schizophrenia and major depression.
description
2002 nî lūn-bûn
@nan
2002 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Neuropeptides involved in the pathophysiology of schizophrenia and major depression.
@ast
Neuropeptides involved in the pathophysiology of schizophrenia and major depression.
@en
type
label
Neuropeptides involved in the pathophysiology of schizophrenia and major depression.
@ast
Neuropeptides involved in the pathophysiology of schizophrenia and major depression.
@en
prefLabel
Neuropeptides involved in the pathophysiology of schizophrenia and major depression.
@ast
Neuropeptides involved in the pathophysiology of schizophrenia and major depression.
@en
P2860
P1476
Neuropeptides involved in the pathophysiology of schizophrenia and major depression.
@en
P2093
David De Wied
Hein O. Sigling
P2860
P2888
P304
P356
10.1080/10298420290031432
P577
2002-08-01T00:00:00Z
P6179
1017941284